相关实验视频

Updated: Jul 9, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

多重系统缩中的勒沃多巴反应性帕金森症的神经病理特征:尸检病例报告和比较的神经病理研究

Mitsuyoshi Tamura¹, Takahiro Takeda², Yoshihisa Kitayama¹

¹Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Frontiers in neurology

|November 30, 2023

概括

在多个系统缩与主要的帕金森症 (MSA-P) 中,利沃多巴的反应与保存的膜结构有关. 这表明,继续接受levodopa治疗可能有利于MSA-P患者,MRI发现正常.

科学领域:

神经病理学神经病理学
神经退行性疾病神经退行性疾病
多巴氨基系统障碍多巴氨基系统障碍

背景情况:

具有主导性帕金森症的多系统缩 (MSA-P) 经常显示出较差的勒沃多巴反应.
利沃多巴在MSA-P中的有效性被假设与胺损伤相关,但确切的病理联系仍然不清楚.

研究的目的:

为了研究对利沃多巴有反应的患者与对利沃多巴无反应的MSA-P患者中尼格罗斯特里亚塔尔多巴激素系统的神经病理特征.
为了确定MSA-P.的勒沃多巴反应变化的病理基础.

主要方法:

临床病理学评估一个对利沃多巴有反应的MSA-P患者和两个对利沃多巴无反应的MSA-P对照.
尸检检查尼格罗斯特里亚塔尔多巴胺类受体密度,多巴胺转运体和α-synuclein.
与死前MRI发现的相关性.

主要成果:

响应勒沃多巴的患者具有保存良好的胺神经元和多巴胺受体免疫反活性.
没有对levodopa反应的患者表现出显著的胺神经元损失和降低多巴胺受体免疫活性.
所有患者都表现出实质性黑色神经元损失和降低多巴胺载体免疫活性.

结论:

在MRI上保存的布塔门和健康的 postsynaptic nigrostriatal 系统与 MSA-P.的勒沃多巴反应相关.
这些发现支持在MSA-P患者中继续使用勒沃多巴治疗,这些患者具有特定的成像特征.

关键词:

利沃多帕 (levodopa) 是一种可以使用的药物.多个系统缩.病理学的病理学预突触多巴胺基纤维的多巴胺基纤维普塔门 (Putamen) 是一个名为普塔门的城市.

更多相关视频

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

相关概念视频

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Lysosomal Hydrolases

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...